Biohaven Ltd. (BHVN) Dividend History

Company News

• BHVN Class Action Alert: Robbins LLP Reminds Biohaven Ltd. Stockholders of the Lead Plaintiff Deadline in the Class Action Against BHVN

  A class action lawsuit has been filed against Biohaven Ltd. alleging that the company misled investors about the regulatory prospects and clinical efficacy of its drug candidates troriluzole and BHV-7000 between March 2023 and May 2025.

  GlobeNewswire Inc.
• BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm

  The Schall Law Firm is pursuing a class action lawsuit against Biohaven Ltd. for allegedly making false and misleading statements about drug candidates troriluzole and BHV-7000, potentially causing investor damages between March 2023 and May 2025.

  Benzinga
• Why Biohaven Stock Dove by Nearly 20% on Thursday

  Biohaven's stock price dropped 19% after the FDA extended the review period for the company's promising pipeline drug troriluzole, which targets a rare brain disorder. The delay is disappointing, but the ultimate fate of the drug depends on the FDA's future actions.

  The Motley Fool
• Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus

  Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.

  Zacks Investment Research

  Featured Companies: ALXO ENTX IMVT
• Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky

  Investors should consider this list of healthcare stocks for 2024

  MarketWatch

  Featured Companies: AAPL ABBV ABT ALKS AMC APGE BSX CING CSTL DHR ENSG EXEL FTRE GME IQV ITGR LH LLY MARA NEO NTRA NVDA PFE PGNY PSCH SLP SOPH SYK TSLA XLV